A Phase 2/3 interventional study of Buprenorphine/naloxone and Placebo in Opioid-use Disorder, sponsored by New York State Psychiatric Institute. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by New York State Psychiatric Institute · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 173 studies testing buprenorphine in Opioid-Related Disorders — 19 open to participants now, 21 under way, 5 of them phase 3. Buprenorphine · Opioid-Related Disorders.
Among the 173 studies testing buprenorphine in Opioid-Related Disorders, this one is the 41st largest by planned enrollment of the 172 interventional ones that give a count, is one of 7 that started in 2023, is one of 10 in phase 2/3, reaches primary completion later than 6 of the 20 other live ones, and was the 150th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →19 of the 173 studies testing buprenorphine in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 19+
Pouya Azar · Sites in Canada
Ages 19+
Rachel R. Luba · Sites in United States
Ages 18–65
Lifespan · Sites in United States
Ages 18+
By country, each count listing its studies:
Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 66 · Phase 3 47 · Phase 4 41
First in 1988; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 19 across the 172 interventional studies. Of the 139 that completed or were terminated, 49 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 173 have an industry lead sponsor. The 10 most frequent:
New York State Psychiatric Institute is the lead sponsor of 436 studies on the registry; 28 are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 46 (88%) have results posted.
42 studies in Opioid-Related Disorders by New York State Psychiatric Institute: 2 open now, 4 under way, 2 of them phase 3. Of 35 finished, 26 (74%) have results posted.
Among the 42 studies in Opioid-Related Disorders by New York State Psychiatric Institute, this one is the 6th largest by planned enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 in phase 2/3, and was the 40th registered.
New York State Psychiatric Institute’s Opioid-Related Disorders studies by the year they started, since 1995.
10 of the studies testing buprenorphine in Opioid-Related Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05011266Phase 3New York State Psychiatric InstituteEfficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder | 2027-01-01 |
| NCT06316830Phase 3Rhode Island HospitalIdentifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose | 2027-08-01 |
| NCT06494904Phase 3Yale UniversityStandard Versus High Dose ED-Initiated Buprenorphine Induction | 2027-09 |
| NCT06051890NYU Langone HealthAssessing Optimal XRB Initiation Points in Jail | 2026-12-01 |
| NCT04464980NYU Langone HealthOptimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 173 studies testing buprenorphine in Opioid-Related Disorders, from their registry updates:
Among New York State Psychiatric Institute’s 42 in Opioid-Related Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effectiveness of a new pharmacological approach to increase efficacy of treatment with extended release naltrexone (XR-naltrexone) for individuals with opioid use disorder by combining it with buprenorphine-naloxone. This is a two arm, double-blind, placebo-controlled study to examine whether addition of buprenorphine-naloxone will improve treatment retention, reduce opioid craving, and improve mood over 24 weeks of treatment with extended release naltrexone (XR-naltrexone) administered every four weeks for a total of 6 injections.
This study will evaluate the effectiveness of a new pharmacological approach to increase efficacy of treatment with extended release naltrexone (XR-naltrexone) for individuals with opioid use disorder by combining it with buprenorphine-naloxone. Adding buprenorphine-naloxone after the patient initiated XR-naltrexone will not produce mu opioid agonist effect but kappa antagonist effects of buprenorphine may provide additional relief of protracted withdrawal, craving, and mood disturbances persisting in patients treated with XR-naltrexone and possibly contributing to premature treatment discontinuation and relapse. This is a parallel arm, double-blind, placebo-controlled study to examine whether addition of buprenorphine will improve treatment retention, reduce opioid craving, and improve mood over 24 weeks of treatment with XR-naltrexone administered every four weeks. Individuals with Opioid Use Disorder (OUD) and beginning treatment with XR-naltrexone for maintenance treatment will be randomized to treatment with adjunctive buprenorphine-naloxone or placebo with 5 additional doses of XR-naltrexone, given every four weeks, and weekly medication management. The study will provide detoxification and a first XR-Naltrexone injection if a participant consents before the first XR-naltrexone injection. In all participants randomization will occur after first XR-NTX injection. Buprenorphine-naloxone (sub-lingual (SL), 4/1 mg/day) or placebo will be started after a first XR-naltrexone dose and tapered off at study completion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Serious medical, psychiatric or substance use disorder that, in the opinion of the study physician, would make a detoxification and naltrexone initiation, or maintenance treatment with XR-NTX in combination with buprenorphine, hazardous (relative ) or requires a different level of care. Examples include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Buprenorphine/naloxone 5.7 mg /1.4 mg/day sub-lingual tablets
Drug: Buprenorphine/naloxone
placebo sub-lingual tablet
Drug: Placebo
Drug pages: BuprenorphineStudies of BuprenorphineBuprenorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · NaloxoneStudies of NaloxoneNaloxone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
5.7 mg buprenorphine/1.4 mg naloxone sub-lingual daily
Also known as: Zubsolv
placebo sub-lingual tablet daily
Also known as: PBO
Proportion of participants receiving XR-naltrexone injections
Proportion of patients successfully retained to receive six consecutive XR-naltrexone injection.
Time frame: 20 weeks
Not enrolling at this site.
Plan to share: Yes — Individual participant data that underlie the results published in this report (after de-identification) (text, tables, figures)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: beginning twelve months and ending 5 years after article publication
Access criteria: to researcher who provides a methodologically sound proposal to achieve aims in approved proposal
Data sharing details ↗ · datashare.nida.nih.gov
Started Apr 2023 (actual). Primary completion is estimated for Jan 2027, 44 months after the start.
Of 18 phase 2/3 interventional studies under Opioid-Related Disorders, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 85. This study's planned 44 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Buprenorphine · Naloxone
New York State Psychiatric Institute →